Abbisko Therapeutics’ Irpagratinib Receives Breakthrough Therapy Designation for HCC Treatment

Abbisko Cayman Limited ( (HK:2256) ) has provided an announcement.

Abbisko Therapeutics has announced that its small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received Breakthrough Therapy Designation from the China National Medical Products Administration for treating Hepatocellular Carcinoma (HCC). This designation is based on promising Phase I clinical trial data and aims to expedite the drug’s approval process, offering new hope for patients with advanced HCC, particularly those with FGF19 overexpression. The company is also conducting a pivotal registrational clinical study and exploring combination therapies to enhance treatment efficacy.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the pharmaceutical industry, focusing on the development of innovative therapies. The company specializes in creating targeted treatments for diseases with significant unmet medical needs, particularly in oncology, with a market focus on precision medicine.

Average Trading Volume: 6,147,188

Technical Sentiment Signal: Buy

Current Market Cap: HK$5.77B

Learn more about 2256 stock on TipRanks’ Stock Analysis page.